These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35333702)

  • 1. A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM
    Thuluva S; Paradkar V; Matur R; Turaga K; Gv SR
    Hum Vaccin Immunother; 2022 Nov; 18(5):2043103. PubMed ID: 35333702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
    Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
    Mohan VK; Varanasi V; Singh A; Pasetti MF; Levine MM; Venkatesan R; Ella KM
    Clin Infect Dis; 2015 Aug; 61(3):393-402. PubMed ID: 25870324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label, comparative, single dose, clinical Phase Ⅰ study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults.
    Choi SK; Baik YO; Kim CW; Kim SK; Oh IN; Yoon H; Yu D; Lee C
    Vaccine; 2021 May; 39(19):2620-2627. PubMed ID: 33849723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
    Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
    Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II/III, Multicenter, Observer-blinded, Randomized, Non-inferiority and Safety, study of typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV® in healthy 6 Months-45 years aged participants.
    Ok Baik Y; Lee Y; Lee C; Kyung Kim S; Park J; Sun M; Jung D; Young Jang J; Jun Yong T; Woo Park J; Jeong S; Lim S; Hyun Han S; Keun Choi S
    Vaccine; 2023 Mar; 41(10):1753-1759. PubMed ID: 36774331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
    Kulkarni PS; Potey AV; Bharati S; Kunhihitlu A; Narasimha B; Yallapa S; Dharmadhikari A; Gavade V; Kamat CD; Mallya A; Sarma AD; Goel S; Pisal SS; Poonawalla CS; Venkatesan R; Jones E; Flaxman A; Kim YC; Pollard AJ;
    Lancet; 2024 Apr; 403(10436):1554-1562. PubMed ID: 38555928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
    Cartee RT; Thanawastien A; Griffin Iv TJ; Mekalanos JJ; Bart S; Killeen KP
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007912. PubMed ID: 31905228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and Safety of Typhoid Conjugate Vaccine in Healthy Indian Subjects: A Randomized, Active-controlled, Comparative Clinical Trial.
    Kundu R; Kandulna AK; Nayak U; Jangid SK; Babu TR; Vukkala R; Sharma S; Goyal VK; Daultani P; Mittal R; Patel P
    Indian Pediatr; 2020 Jul; 57(7):625-630. PubMed ID: 32727938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or measles-mumps-rubella vaccines in 8-9 months-old Indian children.
    Vadrevu KM; Dugyala R; Mahantashetti NS; Khalatkar V; Murthy K; Mogre S; Mitra M
    Hum Vaccin Immunother; 2022 Dec; 18(7):2150030. PubMed ID: 36476258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal.
    Chaudhary S; Shah GS; Bhatta NK; Poudel P; Rai B; Uranw S; Tripathi PM; Khanal B; Ghimire A; Rai N; Gupta BP; Vemula S; Wartel TA; Sahastrabuddhe S; Saluja T
    Hum Vaccin Immunother; 2023 Dec; 19(1):2203634. PubMed ID: 37128723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.
    Capeding MR; Teshome S; Saluja T; Syed KA; Kim DR; Park JY; Yang JS; Kim YH; Park J; Jo SK; Chon Y; Kothari S; Yang SY; Ham DS; Ryu JH; Hwang HS; Mun JH; Lynch JA; Kim JH; Kim H; Excler JL; Sahastrabuddhe S
    Vaccine; 2018 Jun; 36(26):3794-3801. PubMed ID: 29776750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination.
    Vadrevu KM; Raju D; Rani S; Reddy S; Sarangi V; Ella R; Javvaji B; Mahantshetty NS; Battu S; Levine MM
    Vaccine; 2021 Oct; 39(45):6682-6690. PubMed ID: 34625288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers.
    Tamrakar D; Poudel P; Thapa P; Singh S; Khadgi A; Thapa S; Tamrakar R; Shrestha A; Madhup S; Rai GK; Gupta BP; Saluja T; Sahastrabuddhe S; Shrestha R
    Hum Vaccin Immunother; 2024 Dec; 20(1):2301631. PubMed ID: 38189360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper.
    Laurens MB; Sirima SB; Rotrosen ET; Siribie M; Tiono A; Ouedraogo A; Liang Y; Jamka LP; Kotloff KL; Neuzil KM
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S59-S66. PubMed ID: 30845330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report.
    Capeding MR; Alberto E; Sil A; Saluja T; Teshome S; Kim DR; Park JY; Yang JS; Chinaworapong S; Park J; Jo SK; Chon Y; Yang SY; Ham DS; Ryu JH; Lynch J; Kim JH; Kim H; Excler JL; Wartel TA; Sahastrabuddhe S
    Vaccine; 2020 Jun; 38(28):4476-4483. PubMed ID: 31585725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infants.
    Saluja T; Rai GK; Chaudhary S; Kanodia P; Giri BR; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    Vaccine; 2022 Sep; 40(40):5828-5834. PubMed ID: 36064672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial.
    Nampota-Nkomba N; Nyirenda OM; Khonde L; Mapemba V; Mbewe M; Ndaferankhande JM; Msuku H; Masesa C; Misiri T; Mwakiseghile F; Patel PD; Patel P; Johnson-Mayo I; Pasetti MF; Heyderman RS; Tracy JK; Datta S; Liang Y; Neuzil KM; Gordon MA; Laurens MB;
    Lancet Glob Health; 2022 Sep; 10(9):e1326-e1335. PubMed ID: 35961356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial.
    Sirima SB; Ouedraogo A; Barry N; Siribie M; Tiono A; Nébié I; Konaté A; Berges GD; Diarra A; Ouedraogo M; Bougouma EC; Soulama I; Hema A; Datta S; Liang Y; Rotrosen ET; Tracy JK; Jamka LP; Oshinsky JJ; Pasetti MF; Neuzil KM; Laurens MB
    Int J Infect Dis; 2021 Jul; 108():465-472. PubMed ID: 34082090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine.
    Medise BE; Soedjatmiko S; Rengganis I; Gunardi H; Sekartini R; Koesno S; Satari HI; Hadinegoro SR; Yang JS; Excler JL; Sahastrabuddhe S; Puspita M; Sari RM; Bachtiar NS
    PLoS One; 2019; 14(2):e0211784. PubMed ID: 30759132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.